We propose that such a study should involve in‐depth biological studies of the tumour samples pre‐ and post‐treatment, with the aim of explaining the mechanism by which some chordomas are primarily resistant or develop secondary resistance to EGFR inhibitors. Here, EGFR is linked to neoplasm.